[1] Guo JS, Wang JY, Chen SH, Deng YP, Gao QY, Liu ZX, Liu J, Lv K, Liu N, Bai GY, Shan CL, Feng XQ *, Li J.*. The natural product micheliolide promotes the nuclear translocation of GAPDH via binding to Cys247 and induces glioblastoma cell death in combination with temozolomide. Biochem Pharmacol. 2025 Jan 23; 233:116759.

[2] Meng Q., Guo J., Lv K., Liu Y., Zhang J., Li M., Cheng X., Chen S., Huo X., Zhang Q. *, Chen Y. *, Li J.*, 5S-Heudelotinone alleviates experimental colitis by shaping the immune system and enhancing the intestinal barrier in a gut microbiota-dependent manner. Acta Pharmaceutica Sinica B, 2024,14(5):2153-2176.

[3] Jin R, Wang J, Li M, Tang T, Feng Y, Zhou S, Xie H, Feng H, Guo J, Fu R, Liu J, Tang Y*, Shi Y, Guo H, Wang Y, Nie F*, Li J.*, Discovery of a Novel Benzothiadiazine-Based Selective Aldose Reductase Inhibitor as Potential Therapy for Diabetic Peripheral Neuropathy. Diabetes. 2024,73(3):497-510.

[4] Lv K., Li M., Sun C., Miao Y., Zhang Y., Liu Y., Guo J., Meng Q., Yao J.*, Zhang G.*, Li J.*, Jingfang Granule alleviates bleomycin-induced acute lung injury via CD200-CD200R immunoregulatory pathway. J Ethnopharmacol, 2023,15, 311:116423.

[5] Guo J., Liu K., Wang J., Jiang H., Zhang M., Liu Y., Shan C., Hu F., Fu W., Zhang C., Li J.*, Chen Y.*, A rational foundation for micheliolide-based combination strategy by targeting redox and metabolic circuit in cancer cells, Biochemical Pharmacology,2022(200): 115037.

[6] Cui Y., Zhang M., Xu H., Zhang T., Zhang S., Zhao X., Jiang P., Li J.*, Ye B., Sun Y., Wang M., Deng Y., Meng Q., Liu Y., Fu Q., Lin J., Wang L.*, Chen Y.*, Elastase Inhibitor Cyclotheonellazole A: Total Synthesis and In Vivo Biological Evaluation for Acute Lung Injury. Journal of Medicinal Chemistry 2022, 73:334.

[7] Liu W., Liu K., Zhang Y., Wang L., Zhang M.*, Li J.*, The Mechanism of Glycosylation in SARS-CoV-2 Infection and Application in Drug Development. Progress in Chemistry, 2021, 33(4):9.

[8] Ding Y, Xue Q, Liu S, Hu K, Wang D, Wang T, Li Y, Guo H, Hao X, Ge W, Zhang Y, Li A, Li J*, Chen Y*, Zhang Q*. Identification of Parthenolide Dimers as Activators of Pyruvate Ki-nase M2 in Xenograft of Glioblastoma Multiforme in vivo. Journal of Medicinal Chemistry, 2020 63 (4): 1597-1611

[9] Guo J., Xue Q., Ma J., Liu K., Ge W., Liu W., Wang J., Zhang M., Li Q., Cai D., Shan C., Zhang C., Liu X., Li J.*, Dimethylaminomicheliolide (DMAMCL) Suppresses the Proliferation of Glioblastoma Cells via Targeting Pyruvate Kinase 2 (PKM2) and Rewiring Aerobic Glycolysis. Frontiers in Oncology, 2019, 9: 993.

[10] Guo J., Zhang G., Ma J., Zhao C., Xue Q., Wang J., Liu W., Wang H., Liu N., Song Q., Li J.*, A detection and identification of O-GlcNAc-modified proteins using 6-azido-6-deoxy-N-acetyl-galactosamine. Organic & Biomolecular Chemistry, 2019,17, 4326-4334.

[11] Li S., Wang J.*, Zang L., Zhu H., Guo J.,Zhang J., Wen L., Chen Y.,Li Y., Chen X., Wang P G.*, Li J.*,Production of Glycopeptide Derivatives for Exploring Substrate Specificity of Human OGA Toward Sugar Moiety. Frontiers in Chemistry, 2019, 6: 646.

[12] Wang H., Guo J., Wang N., Wang J., Xue Q., Wang J., Liu W., Liu K., Cao X ., Zhao W., Xi R., Niu Y., Wang P., Li J.*, Ac4GlcNAcF3, an OGT-tolerated but OGA-resistant regulator for O-GlcNAcylation.  Bioorganic & Medicinal Chemistry Letters, 2019.2.15, 29(6): 802~805.

[13] Li J., Li S., Guo J., Li Q., Long J., Ma C., Ding Y., Yan C., Li L., Wu Z., Zhu H., Li K., Wen L., Zhang Q., Xue Q., Zhao C., Liu N., Ivanov I., Luo M., Xi R., Long H., Wang PG., Chen Y.., Natural Product Micheliolide (MCL) Irreversibly Activates Pyruvate Kinase M2 and Suppresses Leukemia. Journal of Medicinal Chemistry, 2018, 61, 4155−4164.

[14] Jiang K., Zhu H., Li L., Guo Y., Gashash E., Ma C., Sun X., Li J.*, Zhang L.*, Wang PG.*. Sialic acid linkage-specific permethylation for improved profiling of protein glycosylation by MALDI-TOF MS. Analytica Chimica Acta, 2017, 981:53-61.

[15] Jiang K., Zhu H., Xiao C., Liu D., Garrett E., Wen L., Ma C.*, Li J.*, Wang PG.*. Solid-phase reductive amination for glycomic analysis. Analytica Chimica Acta, 2017, 962:32-40.

[16] Wen L., Jiang K., Zheng Y., Zhang M., Kondengaden SM., Li S., Huang K., Li J., Song J., Wang PG. Two-step Chemoenzymatic Detecting N-Acetylneuraminic acid-α(2-3)- galactose Glycans. JACS, 2016, 138 (36): 11473–11476.

[17] Wu Z., Jiang K., Zhu H., Ma C., Yu Z., Li L., Guan W., Liu Y., Zhu H., Chen Y., Li J., Cheng J., Wang PG., Site-directed glycosylation of peptide/protein with homogeneous O-linked eukaryotic N-glycans. Bioconjugate chemistry 2016, 27 (9), 1972–1975.

[18] Li J., Wen L., Zhu H., Li S., Huang K., Li X., Ma C., Qu J., Parameswaran A., Song J., Zhao W., Wang PG. An OGA-resistant Probe Allow Specific Visualization and Accurate Identification of O-GlcNAc-modified Proteins in Cells. ACS Chem Biol, 2016, 11 (11): 3002–3006.

[19] Li S., Zhu H., Wang J., Wang X., Li X., Ma C., Wen L., Yu B., Wang Y., Li J*., Wang PG.* Comparative analysis of Cu (I)-catalyzed alkyne-azide cycloaddition (CuAAC) and strain-promoted alkyne-azide cycloaddition (SPAAC) in O-GlcNAc proteomics. Electrophoresis. 2016, 37(11): 1431-1436.

[20] Li Z., Li T., Dai S., Xie X., Ma X., Zhao W., Li J.* & Wang P. G*. New insights into the pharmacological chaperone activity of C2 — substituted glucoimidazoles for the treatment of gaucher disease. ChemBioChem, 2013, 14 (10): 1239- 1247.

[21] Li T., Guo L., Zhang Y., Wang J., Zhang Z., Li J., Zhang W., Lin J., Zhao W.*, Wang P.G*. Structure-activity relationships in a series of C2-substituted gluco-configured tetrahydroimidazopyridines as β-glucosidase inhibitors. Bioorg Med Chem., 2011,19(7): 2136-2144.